The Latest Cardiac and Vascular News
– Results from the placebo-controlled study in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) were presented in a Late Breaking Clinical Trial Plenary Session at the HFSA Annual Scientific Meeting 2024 – – Data showed patients treated with HU6…
BENTONVILLE, Ark., Sept. 30, 2024 /PRNewswire/ — HeartX, powered by HealthTech Arkansas and MedAxiom — along with numerous leading cardiology practices in Arkansas and around the country — has selected four startup healthcare companies to participate in its 2024 accelerator program….
Istaroxime treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or clinically significant arrythmias
– Acoramidis treatment led to a highly significant reduction in all-cause mortality (ACM) and recurrent cardiovascular-related hospitalizations (CVH) at Month 30 compared with placebo
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), were presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions by Anjali T. Owens, M.D., Medical Director of the Center for Inherited Cardiac Disease and Assistant Professor of Medicine at the University of Pennsylvania.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that five presentations and one poster across its commercial and development portfolio will be presented at the CHEST 2024 Annual Meeting hosted by the American College of Chest Physicians taking place October […]
PROVIDENCE, R.I., Sept. 24, 2024 /PRNewswire/ — Findings from a new systematic review, titled “Chest Pain in Primary Care: A Systematic Review of Risk Stratification Tools to Rule Out Acute Coronary Syndrome,” published in Annals of Family Medicine, suggest that high-sensitivity troponin…
-BLA to be Supported by Existing and Natural History Cardiac Data as Discussed with the FDA-
– New data from the HuMAIN study, which met the primary endpoint of weight loss and several efficacy and pharmacodynamic secondary endpoints, will be presented in a Late Breaking Clinical Research Session – – HU6, a novel oral, once-daily Controlled Metabolic Accelerator, is a new class…
BEIJING, Sept. 23, 2024 /PRNewswire/ — Professor Luo Min, from Beijing Yuhe Integrated Traditional Chinese and Western Medicine Rehabilitation Hospital, has been invited to attend the 36th World Congress on Cardiology and Heart Disease on October 17-18, 2024 in London to introduce his…
